Eli Lilly has announced a significant strategic expansion into the infectious disease sector, revealing plans to acquire three biotech firms for a combined total of nearly $4 billion in cash. The move marks a pivot for the pharmaceutical giant, which is looking to bolster its research and development capabilities by integrating specialized vaccine and pathogen-fighting technologies into its existing portfolio.

The acquisitions include Curevo, LimmaTech Biologics, and the Vaccine Company, with purchase prices set at $1.5 billion, $780 million, and $1.55 billion, respectively. According to Daniel M. Skovronsky, the company’s chief scientific and product officer, this investment represents a shift toward preventative medicine, aiming to address diseases at their source rather than focusing solely on reactive treatments.

Each acquired firm brings a unique technological focus to Eli Lilly. Curevo offers a shingles vaccine designed for improved tolerability, while LimmaTech Biologics specializes in combating antibiotic-resistant bacterial pathogens such as chlamydia and gonorrhea. Meanwhile, the Vaccine Company contributes advanced nanoparticle delivery systems capable of targeting viral threats like the Epstein-Barr virus.

This expansion comes as Eli Lilly continues to dominate the weight loss and diabetes market with its flagship products, Zepbound and Mounjaro. Despite maintaining a strong 60.1% share of the U.S. obesity drug market, the company is diversifying its pipeline to maintain long-term growth and stay ahead of intense competition from rivals like Novo Nordisk.